Research Analysts Offer Predictions for BNTC Q1 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC) – HC Wainwright issued their Q1 2027 EPS estimates for shares of Benitec Biopharma in a research note issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will earn ($0.32) per share for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q2 2027 earnings at ($0.33) EPS, Q3 2027 earnings at ($0.36) EPS and Q4 2027 earnings at ($0.39) EPS.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03).

Other research analysts have also issued research reports about the company. TD Cowen reiterated a “buy” rating on shares of Benitec Biopharma in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Wednesday, January 21st. Zacks Research upgraded shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Finally, Wall Street Zen downgraded shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Benitec Biopharma presently has an average rating of “Moderate Buy” and an average price target of $27.67.

Benitec Biopharma Stock Performance

NASDAQ BNTC opened at $10.91 on Wednesday. The stock’s fifty day moving average is $11.87 and its two-hundred day moving average is $13.07. The firm has a market capitalization of $374.76 million, a P/E ratio of -9.57 and a beta of 0.31. Benitec Biopharma has a fifty-two week low of $9.85 and a fifty-two week high of $17.15.

Institutional Trading of Benitec Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BNTC. RA Capital Management L.P. purchased a new stake in Benitec Biopharma during the 4th quarter worth about $24,920,000. Suvretta Capital Management LLC increased its stake in shares of Benitec Biopharma by 16.9% during the fourth quarter. Suvretta Capital Management LLC now owns 11,548,351 shares of the biotechnology company’s stock worth $155,556,000 after buying an additional 1,671,845 shares during the period. Siren L.L.C. acquired a new stake in Benitec Biopharma in the fourth quarter valued at approximately $10,439,000. Alyeska Investment Group L.P. purchased a new position in Benitec Biopharma in the fourth quarter worth approximately $10,102,000. Finally, Balyasny Asset Management L.P. purchased a new position in Benitec Biopharma in the fourth quarter worth approximately $8,776,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Insider Activity

In related news, Director Suvretta Capital Management, L acquired 77,387 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were purchased at an average cost of $13.44 per share, for a total transaction of $1,040,081.28. Following the acquisition, the director owned 9,700,195 shares in the company, valued at $130,370,620.80. The trade was a 0.80% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have purchased 190,364 shares of company stock valued at $2,442,105. 4.80% of the stock is currently owned by insiders.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.